The FDA is escalating enforcement against illegal peptide sales, and the scope of its scrutiny now extends well beyond copycat GLP-1 weight-loss drugs. Reports on October 3–4, 2026, describe a coordinated posture in which the agency is acting against both large compounding pharmacies and small online peptide vendors at the same time.
According to Fortune, an FDA advisory panel has recommended adding six unapproved peptides to the bulk compounding list, a move that would restrict pharmacies from compounding those substances if finalized. The panel’s vote is non-binding and does not itself constitute a final FDA decision. Separately, CBS News reported details of the FDA’s September 18 warning letter to Empower Pharmacy, one of the country’s largest compounding pharmacies, over what the agency described as “inordinate amounts” of copycat GLP-1 drugs.
Together, the actions suggest the agency is rejecting the two main legal arguments that have shielded the gray-market peptide trade: large-scale compounding and so-called research-use-only (RUO) labeling.
What happened
Several distinct enforcement and regulatory developments are in motion:
- Advisory panel recommendation. An FDA advisory panel recommended adding six unapproved peptides to the bulk compounding list, according to Fortune. The recommendation is not a final agency decision, but it signals which substances may face compounding restrictions next. An obesity expert quoted in the reporting called for the “compounding craze” to stop.
- Warning letter to Empower Pharmacy. The FDA sent a warning letter on September 18 to Empower Pharmacy over the production of what the agency characterized as “inordinate amounts” of copycat GLP-1 drugs, CBS News reported.
- Vitamin additions called pretextual. The FDA has now stated in writing that vitamin additions to GLP-1 products are pretextual — a direct rejection of a common formulation strategy used to distinguish compounded products from approved drugs.
- Warning letters to online vendors. In August, the FDA issued warning letters to five online peptide vendors for marketing unapproved peptide products, including PT-141 and tesamorelin. Legal experts are now analyzing those letters.
Why it matters
The FDA’s enforcement posture is expanding from GLP-1 copycats to the broader peptide market. The agency is pursuing two very different targets simultaneously: a large 503A compounding pharmacy and small online sellers. That dual-track approach suggests the agency views both mass-copycat compounding and RUO-labeling as inadequate legal shields.
The affected groups are broad. Telehealth peptide platforms, 503A compounding pharmacies, online peptide vendors, consumers who source peptides outside licensed pharmacies, and peptide prescribers all face increased exposure to enforcement risk or disruption of supply.
The advisory panel’s recommendation on six additional peptides, if adopted by the FDA, could further narrow what compounders are permitted to make — a decision that would ripple through telehealth platforms that have built business models around compounded peptide products.
What to watch next
- Whether the FDA formally adds the six recommended peptides to the bulk compounding list, which would convert a non-binding panel vote into binding regulatory restrictions.
- How Empower Pharmacy responds to the September 18 warning letter, and whether further enforcement follows.
- Whether the FDA’s written position that vitamin additions are pretextual leads to additional warning letters against compounders using similar formulation strategies.
- Legal expert analysis of the August warning letters to the five online vendors, which may clarify how the agency treats RUO-labeled peptide sales going forward.
Sources
- Fortune — FDA enforcement and compounding coverage (October 3, 2026)
- CBS News — FDA warning letter to Empower Pharmacy
Industry information only. Not medical or legal advice.
